181
12.
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T,Jacobson
I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV
infection. N Engl J Med 2014;370:211–221.
13.
Afdhal N, Everson G, Calleja JL, McCaughan G, Symonds WT, Denning J, et al.
Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal
hypertension with and without decompensation: early virologic response and
safety. J Hepatol 2014;60:S28.
14.
Flamm SL, Everson GT, Charlton M, Denning JM, Arterburn S, Brandt-Sarif T,et
al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with
decompensated cirrhosis: preliminary results of a prospective,multicenter study.
Hepatology 2014;60:320A.
15.
Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, Kim BK, et al. Lower
incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with
sustained virological response by pegylated interferon and ribavirin.Dig Dis Sci
2015;60:573–581.
16.
Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of
hepatitis C virus infection and the development of hepatocellular carcinoma: a
meta-analysis of observational studies. Ann Intern Med 2013;158:329–337.
17.
Singal AK, Freeman Jr DH, Anand BS. Meta-analysis: interferon improves
outcomes following ablation or resection of hepatocellular carcinoma. Aliment
Pharmacol Ther 2010;32:851–858.
18.
Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis
C virus kinetics during and immediately after liver transplantation. Hepatology
2002;35:680–687.
19.
Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal
transplantation. Transplantation 2002;74:427–437.
20.
Curry MP, Forns X, Chung RT, Terrault NA, Brown Jr R, Fenkel JM, et al. Sofosbuvir
and ribavirin prevent recurrence of HCV infection after liver transplantation: an
open-label study. Gastroenterology 2015;148:100–107.
21.
Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/
r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.N Engl J Med
2014;370:1973–1982.
22.
Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association
between hepatitis C infection and survival after orthotopic liver transplantation.
Gastroenterology 2002;122:889–896.
23.
Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High
incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following
transplantation: relationship with rejection episodes.Hepatology 1999;29:250–256.
24.
Blasco A, Forns X, Carrion JA, Garcia-Pagan JC, Gilabert R, Rimola A, et al.
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C
recurrence after liver transplantation. Hepatology 2006;43:492–499.
25.
Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al.
Fibrosis progression after liver transplantation in patients with recurrent hepatitis
C. J Hepatol 2004;41:830–836.
26.
Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of
antiviral therapy in patients with recurrent hepatitis C following liver transplantation.
Am J Transplant 2008;8:679–687.
27.
Gambato M, Lens S, Navasa M, Forns X. Treatment options in patients with
decompensated cirrhosis, pre- and post-transplantation. J Hepatol 2014;61:S120–
Özel Hasta Gruplarýnda HCV Enfeksiyonunun Tedavisi
